Poging GOUD - Vrij

FDA Cites Failure to Report GLP-1 Risks

The Wall Street Journal

March 11, 2026

Novo Nordisk said it is working quickly to respond to the FDA's request.

- BY ELIAS SCHISGALL

Novo Nordisk received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the company's GLP-1 treatments.

Dit verhaal komt uit de March 11, 2026-editie van The Wall Street Journal.

Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.

Bent u al abonnee? Aanmelden